Astellas Pharma Inc. (ALPMF) 은(는) 상장 기업입니다 헬스케어 섹터의 제약 산업에서 운영. 본사 소재지는 Tokyo, 일본. 현재 CEO는 Naoki Okamura.
ALPMF 을(를) 보유 IPO 날짜 2010-04-26, 14,754 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $29.61B.
Astellas Pharma Inc. is a Japan-based pharmaceutical company founded in 1923 that manufactures, markets, and distributes medicines globally across oncology, urology, immunology, and infectious disease. The company's key products include XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, PADCEV for urothelial cancer, Myrbetriq for overactive bladder, Evrenzo for anemia in chronic kidney disease, and Prograf for transplant immunosuppression. Astellas maintains an extensive pipeline and strategic partnerships with leading institutions including Merck, Harvard University, and CytomX Therapeutics, as well as collaborations in emerging areas such as targeted radiotherapy, cell therapy, and epigenetic research. The company is headquartered in Tokyo and operates a diversified portfolio of prescription and specialty pharmaceutical products serving major markets worldwide.
